slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,471
Current window 34,561-34,590
Pages 3,950
Rows per page 30
Component
34,561-34,590 of 118,471
113
The slide uses a critical tone to challenge the integrity of the reported clinical trial data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
119
The slide uses direct quotes from the EMA's CHMP assessment report to highlight regulatory discrepancies.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
125
The slide uses a specific data table to support a broader narrative of corporate non-transparency regarding PK data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
130
The slide uses direct citations from FDA and research documents to highlight the discrepancy between single-dose study designs and the need for steady-state peak plasma concentration analysis.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
136
Includes a linear regression equation Y=14.62*X+53.34 and a scatter plot with error bars.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
138
The slide uses direct excerpts from the drug's prescribing information to build a case against its safety profile.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
140
The slide uses a quote from a consultant to challenge the validity of the company's (Harmony) data submitted to the FDA.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
145
The slide contrasts the author's critique with a direct excerpt from an FDA Clinical Pharmacology Review.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
146
The slide uses a 'red flag' narrative to challenge the integrity of clinical trial data reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
147
The slide uses direct excerpts from FDA documents and product labels to highlight a contradiction in clinical trial methodology.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
150
The slide uses a specific calculation (153 ng/mL * 4 * 2 = 1224 ng/mL) to quantify risk.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
156
The slide uses a combination of narrative analysis and a specific case study excerpt to challenge the safety profile of pitolisant.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
157
The slide presents clinical case summaries to address potential safety concerns regarding cardiac events.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
158
The slide uses direct quotes from FDA clinical reviews to highlight the discrepancy between pre-approval assumptions and post-approval safety signals.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
161
The slide uses a 'fraud-exposure' or 'investigative' tone to question the lack of public data on a specific study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
163
The slide uses a 'villain' narrative to frame the company's non-disclosure as intentional concealment.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
164
The slide uses a combination of original analysis and cited medical literature to challenge the transparency of clinical trial reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
169
The slide uses a direct quote from an FDA clinical review to demonstrate a lack of oversight regarding a specific medical signal.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
183
The slide presents a clinical case study narrative, likely for pharmacovigilance or safety analysis.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
184
The slide highlights a potential cover-up or reporting discrepancy regarding a patient seizure.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
187
This is a clinical case report document from the FDA Adverse Event Reporting System (FAERS).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
191
The slide highlights a discrepancy between patient belief and sponsor assessment regarding drug causality.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
193
The slide uses a narrative structure to expose a potential cover-up or reporting failure regarding a serious adverse event.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
194
This is a medical case report summary, likely used for pharmacovigilance or safety analysis.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
195
This is a pharmacovigilance case report summary.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
196
The slide presents a specific pharmacovigilance case report, highlighting a positive dechallenge.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
197
This is a clinical case study/adverse event report sourced from FDA FAERS data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
198
This appears to be a medical case report document from the FDA FAERS database.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
199
This is a clinical case study/adverse event report sourced from FDA FAERS data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
200
This is a pharmacovigilance case report summary.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits